Taysha Gene Therapies, Inc. (TSHA)
$5.87-$0.09 (-1.51%) Today
Sean P. Nolan - OfficerSean P. Nolan - OfficerTaysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 200,000 | $1.25M |
| Grant or award | 8 | 256,024 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
18 Form 4 filings on record, the earliest from Jun 2, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 200,000 | $6.24 | $1.25M | |
| John A. Stalfort III | Grant or award | Common Stock | 21,335 | $0.00 | - | |
| John A. Stalfort III | Grant or award | Stock Option (right to buy) | 42,671 | $0.00 | - | |
| Phillip B. Donenberg | Grant or award | Common Stock | 21,335 | $0.00 | - | |
| Phillip B. Donenberg | Grant or award | Stock Option (right to buy) | 42,671 | $0.00 | - | |
| Alison S. Long | Grant or award | Common Stock | 21,335 | $0.00 | - | |
| Alison S. Long | Grant or award | Stock Option (right to buy) | 42,671 | $0.00 | - | |
 Laura Sepp-Lorenzino | Grant or award | Common Stock | 21,335 | $0.00 | - | |
| Laura Sepp-Lorenzino | Grant or award | Stock Option (right to buy) | 42,671 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 19,021 | $1.71 | $33K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 200,000 | $4.46 | $892K | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 19,021 | $0.00 | - | |
| Kamran Alam - Officer | Open-market sale | Common Stock | 1,655 | $4.52 | $7K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 89,132 | $4.75 | $423K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 26,918 | $4.61 | $124K | |
| Sean P. Nolan - Officer | Open-market sale | Common Stock | 136,789 | $4.75 | $650K | |
| Sean P. Nolan - Officer | Open-market sale | Common Stock | 41,312 | $4.61 | $190K | |
| Kamran Alam - Officer | Open-market sale | Common Stock | 78,968 | $4.75 | $375K | |
| Kamran Alam - Officer | Open-market sale | Common Stock | 23,849 | $4.61 | $110K | |
| Kamran Alam - Officer | Grant or award | Common Stock | 359,000 | $0.00 | - | |
| Kamran Alam - Officer | Grant or award | Employee Stock Option (right to buy) | 231,000 | $0.00 | - | |
| Sean P. Nolan - Officer | Grant or award | Common Stock | 1,008,000 | $0.00 | - | |
| Sean P. Nolan - Officer | Grant or award | Employee Stock Option (right to buy) | 648,000 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 111,324 | $0.70 | $78K | |
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 88,676 | $1.71 | $152K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 200,000 | $4.71 | $942K | |
| Sukumar Nagendran - Officer | Grant or award | Common Stock | 427,000 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 111,324 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 88,676 | $0.00 | - | |
| Sukumar Nagendran - Officer | Grant or award | Employee Stock Option (right to buy) | 274,000 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 70,172 | $0.70 | $49K | |
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 39,953 | $1.71 | $68K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 110,125 | $4.75 | $523K | |
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 260,047 | $1.71 | $445K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 260,047 | $4.51 | $1.17M | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 70,172 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 39,953 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 260,047 | $0.00 | - | |
| Sukumar Nagendran - Officer | Option exercise | Common Stock | 41,150 | $0.70 | $29K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 200,000 | $3.23 | $646K | |
| Sukumar Nagendran - Officer | Option exercise | Employee Stock Option (right to buy) | 41,150 | $0.00 | - | |
| Kamran Alam - Officer | Open-market sale | Common Stock | 54,491 | $2.85 | $155K | |
| Sukumar Nagendran - Officer | Open-market sale | Common Stock | 57,054 | $2.85 | $163K | |
| Phillip B. Donenberg | Grant or award | Common Stock | 56,623 | $0.00 | - | |
| Phillip B. Donenberg | Grant or award | Stock Option (right to buy) | 113,246 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
Taysha Gene Therapies, Inc. (TSHA) had 5 insider filings in the last 90 days, with the most recent on 2026-07-10. The full record for TSHA runs to 18 Form 4 filings, the earliest from 2025-06-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TSHA were filed in the last 90 days.
1 insider sale of TSHA was filed in the last 90 days, totaling $1.25M.
This page tracks TSHA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TSHA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
